SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

Name: SR ONE CAPITAL MANAGEMENT, LP Q2 2026 13F Filing | 13F Explorer
Creator: SR ONE CAPITAL MANAGEMENT, LP
Published: 2026-08-12

Location: Redwood City, CA

CIK: 0001910264 · Show all filings

Period: Q2 2026 (← Previous)

Filing Date: Aug 12, 2026

Total Value: $1.039B (100.0% shares, 0.0% debt)

Holdings (15)

New Positions (3)

AVLN Avalyn Pharma, Inc 10.5%

Value $109M Shares 3,308,649 Est. Cost $32.92 Unrealized —

ODTX Odyssey Therapeutics, Inc. 6.8%

Value $71M Shares 3,794,883 Est. Cost $18.71 Unrealized —

MOBI Mobia Medical, Inc 2.6%

Value $26.61M Shares 1,986,072 Est. Cost $13.40 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
AVLN	Avalyn Pharma, Inc	3,308,649	$109M	10.5%	$32.92	—	Common Stock	05348Y105
ODTX	Odyssey Therapeutics, Inc.	3,794,883	$71M	6.8%	$18.71	—	Common Stock	67613T104
MOBI	Mobia Medical, Inc	1,986,072	$26.61M	2.6%	$13.40	—	Common Stock	60705V103

Increased Positions (1)

ORIC ORIC Pharmaceuticals, Inc. 4.8%

Value $49.98M (-14.5%) Shares 4,615,384 (+2.2%) Est. Cost $6.80 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ORIC	ORIC Pharmaceuticals, Inc.	4,615,384 (+2.2%)	$49.98M (-14.5%)	4.8%	$6.80	—	Common Stock	68622P109

Exited Positions (2)

ACLX Arcellx, Inc. 25.9%

Value $269M Shares 2,346,630 Est. Cost $16.72 Unrealized —

ORKA Oruka Therapeutics, Inc 2.0%

Value $21.11M Shares 430,330 Est. Cost $33.46 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	Arcellx, Inc.	2,346,630	$269M	25.9%	$16.72	—	—	03940C100
ORKA	Oruka Therapeutics, Inc	430,330	$21.11M	2.0%	$33.46	—	—	687604108

Unchanged Positions (11)

MANE Veradermics, Inc. 28.4%

Value $295M Shares 2,401,868 Est. Cost $63.15 Unrealized —

ZBIO Zenas BioPharma, Inc 12.3%

Value $128M Shares 5,037,854 Est. Cost $18.35 Unrealized —

DSGN Design Therapeutics, Inc. 9.1%

Value $94.44M Shares 6,526,476 Est. Cost $16.67 Unrealized —

CRSP CRISPR Therapeutics AG 10.7%

Value $111M Shares 2,038,763 Est. Cost $64.71 Unrealized —

ALMS Alumis Inc. 5.3%

Value $55.15M Shares 1,959,896 Est. Cost $13.30 Unrealized —

OCS Oculis Holding AG 0.9%

Value $8.891M Shares 641,022 Est. Cost $20.25 Unrealized —

ENGN enGene Holdings Inc. 0.1%

Value $1.294M Shares 747,750 Est. Cost $11.04 Unrealized —

NKTX Nkarta, Inc. 0.9%

Value $9.433M Shares 3,333,333 Est. Cost $11.49 Unrealized —

RARE Ultragenyx Pharmaceutical Inc. 0.4%

Value $4.6M Shares 137,753 Est. Cost $32.88 Unrealized —

MLYS Mineralys Therapeutics Inc. 4.1%

Value $42.2M Shares 1,563,966 Est. Cost $14.62 Unrealized —

SPRY ARS Pharmaceuticals, Inc. 3.1%

Value $32.14M Shares 4,012,903 Est. Cost $6.79 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
MANE	Veradermics, Inc.	2,401,868	$295M	28.4%	$63.15	—	Common Stock	922967104
ZBIO	Zenas BioPharma, Inc	5,037,854	$128M	12.3%	$18.35	—	Common Stock	98937L105
DSGN	Design Therapeutics, Inc.	6,526,476	$94.44M	9.1%	$16.67	—	Common Stock	25056L103
CRSP	CRISPR Therapeutics AG	2,038,763	$111M	10.7%	$64.71	—	Common Shares	H17182108
ALMS	Alumis Inc.	1,959,896	$55.15M	5.3%	$13.30	—	Common Stock	022307102
OCS	Oculis Holding AG	641,022	$8.891M	0.9%	$20.25	—	Ordinary Shares	H5870P102
ENGN	enGene Holdings Inc.	747,750	$1.294M	0.1%	$11.04	—	Common Shares	29286M105
NKTX	Nkarta, Inc.	3,333,333	$9.433M	0.9%	$11.49	—	Common Stock	65487U108
RARE	Ultragenyx Pharmaceutical Inc.	137,753	$4.6M	0.4%	$32.88	—	Common Stock	90400D108
MLYS	Mineralys Therapeutics Inc.	1,563,966	$42.2M	4.1%	$14.62	—	Common Stock	603170101
SPRY	ARS Pharmaceuticals, Inc.	4,012,903	$32.14M	3.1%	$6.79	—	Common Stock	82835W108